Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?

Basit Öğe Kaydı
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000-0002-1630-2033en_US
dc.authorid0000-0002-5924-7476
dc.authorid0000-0002-6839-2632
dc.authorid0000-0002-4542-4064
dc.authorid0000-0002-4313-8478
dc.contributor.authorTekçe, Buket Kin
dc.contributor.authorÜyetürk, Ümmügül
dc.contributor.authorTekçe, Hikmet
dc.contributor.authorÜyetürk, Uğur
dc.contributor.authorAktaş, Gülali
dc.contributor.authorAkkaya, Akcan
dc.date.accessioned2021-06-23T19:42:38Z
dc.date.available2021-06-23T19:42:38Z
dc.date.issued2015
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1(U) and KIM-1(S)) concentrations were useful in predicting cisplatin-induced AKI in early stages. Methods We prospectively analysed 22 patients on cisplatin treatment. KIM-1(S) and KIM-1(U) concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT(1)], third [AT(3)] and fifth [AT(5)] day after treatment). Results KIM-1(U) concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1(U) concentrations of the same patients BT (P=0.009) and to AT(1)-KIM-1(U) concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT(1)-KIM-1(U) concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1(S) concentrations were not significantly changed between BT and AT periods. Conclusions KIM-1(U) concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.en_US
dc.identifier.doi10.1177/0004563214528312
dc.identifier.endpage94en_US
dc.identifier.issn0004-5632
dc.identifier.issn1758-1001
dc.identifier.issue1en_US
dc.identifier.pmid24670880en_US
dc.identifier.scopus2-s2.0-84918775812en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage88en_US
dc.identifier.urihttps://doi.org/10.1177/0004563214528312
dc.identifier.urihttps://hdl.handle.net/20.500.12491/8556
dc.identifier.volume52en_US
dc.identifier.wosWOS:000346418300011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTekçe, Buket Kin
dc.institutionauthorÜyetürk, Ümmügül
dc.institutionauthorTekçe, Hikmet
dc.institutionauthorÜyetürk, Uğur
dc.institutionauthorAktaş, Gülali
dc.institutionauthorAkkaya, Akcan
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofAnnals Of Clinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectKidney Injury Molecule-1en_US
dc.subjectCisplatinen_US
dc.subjectAcute Kidney Injuryen_US
dc.subjectBiomarkeren_US
dc.titleDoes the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
buket-kin-tekce.pdf
Boyut:
192.16 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu